LEADS has announced a company-wide fundraising initiative to support a seven-year-old patient from Kemerovo diagnosed with Duchenne muscular dystrophy. The campaign aims to cover the cost of specialized medication for the child, who is related to the studio’s webmaster, Pavel Olkhovik.
Medical Condition and Treatment Plan
Duchenne muscular dystrophy is a progressive disorder that causes continuous muscle degeneration. Without intervention, the condition severely limits physical mobility and respiratory function. Medical professionals have identified Elevidys as a targeted therapy capable of addressing the underlying cause of the disease.The total expense for the required medication reaches approximately ₽250,000,000. Current contributions have accumulated to ₽6,000,000. LEADS has allocated initial funds toward the campaign and is requesting additional financial support from its community. Donations can be processed through Sber, VTB, Alfa-Bank, T-Bank, and Gazprombank accounts.
Each transfer requires the reference note "For Roma's treatment" to ensure proper allocation.
The details were shared by LEADS management.